PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA

PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA

Bibliographic Details
Main Authors:	S. Bougherira, S. Bentorki, F. Grifi
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850760.69913.0b

Similar Items

PB2045: POLYCYTHEMIA VERA IN YOUNG SUBJECTS: ABOUT A COHORT OF 11 CASES
by: S. Bougherira, et al.
Published: (2022-06-01)

Economic evaluation of denosumab in the prevention of skeletal-related events in patients with multiple myeloma in Mexico
by: Fernando Carlos-Rivera, et al.
Published: (2022-04-01)

PB2142: SERUM OSTEOCALCIN AS A PREDICTOR FOR THE RISK OF DENOSUMAB AND BISPHOSPHONATE INDUCED HYPOCALCEMIA IN MYELOMA PATIENTS WITH HYPERCALCEMIA
by: Yuehua Ding, et al.
Published: (2023-08-01)

Safety and efficacy of denosumab in postmenopausal somen with osteoporosis
by: Dilsad Sindel, et al.
Published: (2020-10-01)

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
by: Anastasilakis AD, et al.
Published: (2012-06-01)

PB2164: EFFICACY AND SAFETY EVALUATION OF IXAZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Wen LI, et al.
Published: (2023-08-01)

Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients
by: Mayuko Hori, et al.
Published: (2022-05-01)

In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.
by: Yan Wang, et al.
Published: (2012-01-01)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
by: Uehara M, et al.
Published: (2018-05-01)

Safety of denosumab in patients with chronic kidney disease
by: Nasra K Al Adhoubi, et al.
Published: (2021-01-01)

The efficacy of denosumab in Korean male patients with osteoporosis
by: Chaiho Jeong, et al.
Published: (2022-09-01)

Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone
by: Luo Y, et al.
Published: (2018-07-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2012-01-01)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
by: Adrian Alegre, et al.
Published: (2011-12-01)

Case Report: Safety and Efficacy of Denosumab in Four Children With Noonan Syndrome With Multiple Giant Cell Lesions of the Jaw
by: Kristen Ferriero, et al.
Published: (2020-09-01)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
by: Yi Chen, et al.
Published: (2021-04-01)

PB2278: INVESTIGATION ON THE STATUS OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA
by: D. Lan, et al.
Published: (2022-06-01)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
by: Yasmine Moutmir, et al.
Published: (2023-08-01)

Safety of denosumab in dialysis patients on calcium and vitamin D supplements
by: Asad Ullah, et al.
Published: (2017-01-01)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
by: Yilin Zhu, et al.
Published: (2020-05-01)

PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
by: Soraya Bougherira
Published: (2023-08-01)

Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
by: N. V. Toroptsova, et al.
Published: (2016-01-01)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
by: Lewiecki EM
Published: (2011-12-01)

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: M. Sasaki, et al.
Published: (2022-06-01)

PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14
by: M. Hultcrantz, et al.
Published: (2022-06-01)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-08-01)

Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
by: Xiaohui Gao, et al.
Published: (2023-11-01)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
by: N. Y. Semenova, et al.
Published: (2022-06-01)

PB2157: AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT NEPHROPATHY
by: Ekaterina Karimova, et al.
Published: (2023-08-01)

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
by: Annita-Ioanna Gkioka, et al.
Published: (2023-08-01)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
by: M. Shokouhi, et al.
Published: (2022-06-01)

SAFETY OF DARATUMUMAB IN FRAIL PATIENTS WITH MULTIPLE MYELOMA
by: TX Carneiro, et al.
Published: (2023-10-01)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
by: Cédric Gillich, et al.
Published: (2023-05-01)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
by: Dawn Swan, et al.
Published: (2023-03-01)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
by: Gils Roex, et al.
Published: (2020-12-01)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
by: Offidani M, et al.
Published: (2021-06-01)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01)

Efficacy and safety of denosumab treatment for Korean patients with Stage 3b–4 chronic kidney disease and osteoporosis
by: Jin Taek Kim, et al.
Published: (2024-01-01)

Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
by: Allan Lipton, et al.
Published: (2012-01-01)